Clinical Trials Logo

Filter by:
NCT ID: NCT03536884 Completed - Clinical trials for Chronic Plaque Psoriasis

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

BE RADIANT
Start date: June 13, 2018
Phase: Phase 3
Study type: Interventional

This is a study to compare the efficacy of bimekizumab versus secukinumab in subjects with moderate to severe chronic plaque psoriasis (PSO).

NCT ID: NCT03535740 Active, not recruiting - Clinical trials for ALK-positive Advanced NSCLC

A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib

ALTA-2
Start date: January 31, 2019
Phase: Phase 2
Study type: Interventional

The primary purpose of this study is to determine the efficacy of brigatinib by confirmed objective response rate (ORR) by response evaluation criteria in solid tumors (Response Evaluation Criteria in Solid Tumors [RECIST]), in participants with ALK+ locally advanced or metastatic NSCLC whose disease has progressed on therapy with alectinib or ceritinib.

NCT ID: NCT03535168 Completed - Cough Clinical Trials

Repeat Doses of BAY1902607 in Healthy Males and Proof of Concept in Chronic Cough Patients

Start date: May 29, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objectives of this study: - To investigate the safety and tolerability of ascending repeated oral doses of BAY1902607 in healthy subjects (Part 1). - To investigate the effect of BAY1902607 on the pharmacokinetics (PK) of a sub-therapeutic 1 mg dose of midazolam (Part 1). - To investigate the safety, tolerability and efficacy of BAY1902607 in patients with refractory chronic cough (Part 2).

NCT ID: NCT03532984 Not yet recruiting - Stroke Clinical Trials

Beam Walking Across the Lifespan for Falls Prediction

BEAM
Start date: June 1, 2018
Phase:
Study type: Observational

Background: Dynamic balance keeps the vertical projection of the center of mass within the base of support while the center of mass moves. The age-related decrease in dynamic balance is a risk factor for falls. Dynamic balance tests are used to predict the risks for falls and eventual falls but the psychometric properties of most tests assessing dynamic balance are unsatisfactory and comprise no actual loss of balance while walking. Objectives: Using beam walking distance as a measure of dynamic balance, we will determine the psychometric properties, lifespan and patient reference values, the relationship with selected 'dynamic balance tests', and the accuracy of beam walking distance to predict falls. Methods: This cross-sectional observational study will examine healthy adults in 7 decades (n=432) at 4 centers. Center 5 will examine patients (n=100) diagnosed with Parkinson's disease, multiple sclerosis, stroke, and balance disorders. At Test 1, all participants will be measured for demographics, medical history, grip and leg strength, short physical performance battery, static balance on a force platform, and dynamic balance using beam walking (4m-long, 4, 8, and 12 cm wide) under single (beam walking only) and dual task conditions (beam walking while concurrently performing an arithmetic task). In addition, cognitive function (global cognition, attention, executive function, processing speed, memory) will be assessed. Patients and healthy participants age 50+ will be additionally measured for fear of falling, history of falls, miniBESTest, functional reach on a force platform, timed up and go, and reactive balance. At Test 2, 7-10 days after Test 1, healthy adults young and age 50+ (n=40) will be re-tested for reliability of beam walking performance. All participants age 50+ will be re-called to report fear of falling and fall history 6 and 12 months after Test 1. Conclusion: The investigators expect to find that beam walking performance vis-à-vis the traditionally used balance outcomes predicts more accurately fall risks and falls.

NCT ID: NCT03532087 Withdrawn - Breast Neoplasms Clinical Trials

Study to Identify the Impact of Denosumab on the Immune System in Patients With HER2 Negative Breast Cancer

PERIDENO
Start date: February 2018
Phase: Phase 2
Study type: Interventional

The aim of this prospective, randomized, multicenter, open-label, explorative phase II study is to identify the impact of (neo)adjuvant denosumab on the systemic immunity and local immunologic microenvironment in postmenopausal patients with HER2 negative non-metastatic primary breast cancer.

NCT ID: NCT03531554 Completed - VLCAD Deficiency Clinical Trials

Acute Nutritional Ketosis in VLCAD Deficiency

Start date: April 1, 2016
Phase: N/A
Study type: Interventional

To test if a ketone-ester based drink can boost muscle mitochondrial function in vivo in patients with VLCADD in order to establish a rational basis for therapeutic use in this disorder.

NCT ID: NCT03531424 Recruiting - Clinical trials for Coronary Artery Disease

Augmented-Reality CTA Plus Angiography vs Angiography Alone for Guiding PCI in Coronary Lesions - Randomized Study

AR-PCI
Start date: April 25, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to compare revascularization strategy and its immediate results after augmented-reality computed tomography angiography (CTA) guided vs. standard angiography guided percutaneous coronary intervention (PCI) in native coronary lesions.

NCT ID: NCT03531333 Active, not recruiting - Glioma Clinical Trials

Intraoperative Ultrasound Guided Glioma Surgery; a Randomised, Controlled Trial.

US-GLIOMA
Start date: November 1, 2016
Phase: N/A
Study type: Interventional

The main goal of high grade glioma (HGG) surgery is to achieve gross total resection (GTR) without causing new neurological deficits1-8. Intraoperative navigated high resolution ultrasound (US) is a promising new tool to acquire real-time intraoperative images to localize and to resect gliomas9-12. The aim of this study was to investigate whether intraoperative guided surgery leads to a higher rate of GTR, when compared with standard non-ultrasound guided surgery.

NCT ID: NCT03530397 Active, not recruiting - Clinical trials for Selected Advanced Solid Tumors

A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors

Start date: April 24, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate MEDI5752 and carboplatin and pemetrexed or paclitaxel or nab-paclitaxel in adult subjects with advanced solid tumors, when administered as a single agent or combined with chemotherapy.

NCT ID: NCT03529045 Active, not recruiting - Epilepsy Clinical Trials

Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System.

CORE-VNS
Start date: February 5, 2018
Phase:
Study type: Observational [Patient Registry]

Multicenter global post-market registry of subjects diagnosed with drug resistant epilepsy and treated with the VNS Therapy System.